Tandem Diabetes expands Mobi Insulin Pump to Android users

Tandem Diabetes Care Inc. announced that its Mobi automated insulin delivery system is now compatible with Android smartphones in the U.S., expanding access beyond the iPhone-only launch in 2024.

The Tandem Mobi mobile app, which allows users to control the insulin pump from their phones, is now available on Google Play for select devices including Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25.

"By expanding to Android, we're broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief executive officer. "It's an exciting milestone that underscores our commitment to delivering choice in diabetes technology."

The Food and Drug Administration cleared the Android version in November 2025, followed by a limited release in December.

Tandem Mobi, marketed as the world's smallest durable automated insulin delivery system, is powered by Control-IQ+ technology. Clinical data shows users achieve 79% time in target glucose range and 90% overnight time in range, with improvements beginning on day one of use.

The pump's compact size allows users to wear it on-body with an adhesive sleeve, clip it to clothing, or slip it into a pocket. The mobile app provides secure connectivity to Tandem's Source platform, enabling communication between patients and healthcare providers.

Tandem Diabetes Care, based in San Diego, trades on the Nasdaq under the symbol TNDM.

Recent advances transform insulin delivery technology

The diabetes technology sector has experienced rapid innovation in automated insulin delivery systems over the past two years, fundamentally changing how millions of Americans manage Type 1 diabetes and insulin-dependent Type 2 diabetes.

Automated insulin delivery systems, often called "artificial pancreas" technology, use continuous glucose monitors and algorithms to automatically adjust insulin delivery throughout the day and night. This represents a significant leap from traditional insulin pumps that require constant manual input from users.

Industry leaders including Medtronic, Insulet Corp., and Tandem have all released next-generation systems since 2023. Medtronic's MiniMed 780G system gained FDA approval for children as young as two years old in 2024, while Insulet's tubeless Omnipod 5 system expanded its algorithm capabilities and smartphone integration.

The trend toward smartphone control has become central to the sector's evolution. Most major manufacturers now offer apps that eliminate the need for separate controller devices, allowing users to manage insulin delivery discreetly from phones they already carry. This smartphone integration also enables better data sharing with healthcare providers through cloud-based platforms.

Clinical outcomes have improved alongside the technology. Recent studies published in diabetes journals show modern automated systems help users maintain blood glucose in target range for more than 70% of the time, compared to roughly 50-60% with traditional pumps. Overnight control has particularly benefited, reducing dangerous low blood sugar episodes while parents sleep.

The miniaturization of pump hardware represents another major advance. Devices have shrunk to roughly half the size of models from five years ago, addressing long-standing complaints about bulkiness and visibility. Some newer pumps weigh less than two ounces fully loaded.

Regulatory approval timelines have also accelerated, with the FDA creating streamlined pathways for interoperable diabetes devices that work across multiple manufacturers' systems.